TBPH Q1 2020 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+272.1% YoY

Gross Profit

$20M100.0% margin

Operating Income

-$72M-364.9% margin

Net Income

-$83M-418.2% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

-32.7%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$56M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$605M

Total Liabilities

$763M

Stockholders' Equity

-$158M

Cash & Equivalents

$333M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$5M	+272.1%
Gross Profit	$20M	-$48M	+141.0%
Operating Income	-$72M	-$74M	+1.6%
Net Income	-$83M	-$73M	-14.4%

Revenue Segments

Co Promote Agreement

$12M59%

Collaborative Arrangement Revenue

$7M33%

License

$2M8%